Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment Dizal has unveiled significant Phase 3 results for ZEGFROVY, showcasing enhanced survival rates in lung cancer patients with EGFR mutations.

Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment #Shanghai #NSCLC #Dizal #ZEGFROVY

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference At the 2025 World Conference on Lung Cancer, Dizal presented innovations in treating non-small cell lung cancer, showcasing promising results with ZEGFROVY and golidocitinib.

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference #China #Shanghai #Dizal #Golidocitinib #ZEGFROVY

Dizal's ZEGFROVY® Emerges as the First Targeted Oral Treatment for NSCLC Dizal's ZEGFROVY® has achieved FDA accelerated approval, marking a breakthrough for treating lung cancer with specific mutations.

Dizal's ZEGFROVY® Emerges as the First Targeted Oral Treatment for NSCLC #Shanghai #United_States #Dizal #Lung_Cancer #ZEGFROVY